Review of inflammatory bowel disease and COVID-19

Sultan, Keith; Mone, Anjali; Durbin, Laura; Khuwaja, Samreen; Swaminath, Arun

doi:10.3748/wjg.v26.i37.0000

Cited by 2 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concomitant azathioprine with golimumab reduced the immunogenicity but increased the risk of death of lymphoma in young patients [17,46–48] . We did not record any adverse events even though golimumab was maintained for >90 weeks during the COVID-19 pandemic [49,50] …”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis

Alhalabi¹,

Eddin²,

Cheha³

et al. 2021

Medicine

View full text Add to dashboard Cite

Introduction: Golimumab is a fully human antitumor necrosis monoclonal antibody that can be administered by either subcutaneous injection or intravenous infusion. Golimumab is approved for the treatment of the adults with rheumatic diseases, and ulcerative colitis, Whereas in children, golimumab is indicated only for the treatment of active polyarticular juvenile idiopathic arthritis. We have written on the off-label use of subcutaneous golimumab, which helped to induce and maintain remission on a low-weight biologically experienced child with steroid-refractory ulcerative colitis flare. Patient concerns: A 13-year-old pancolitis Syrian boy presented with abdominal pain and six to seven times bloody diarrhea. The child had treated with mesalamine 80 mg/kg/day, azathioprine 2.5 mg/kg/day, infliximab with an induction dose of 5 mg/kg at weeks 0, 2, and 6 followed by 5 mg/kg every 8 weeks. Infliximab did not maintain remission as the patient suffered from two flares that required hospital admission, intravenous corticosteroids, and infliximab escalation. Initial tests disclosed leukocytosis, anemia, hypoalbuminemia, an elevation in C-reactive protein and fecal calprotectin. All Stool studies were negative including routine stool cultures, Clostridium difficile toxin, Escherichia coli O157:H7, Cryptosporidium, and microscopy for ova and parasites. A sigmoidoscopy revealed multiple large ulcerations and spontaneous bleeding, colon biopsies were negative for Clostridium difficile and Cytomegalovirus. Cyclosporine, tacrolimus, and adalimumab were unavailable in Syria. Child's parents opposed colectomy as a treatment option. Diagnosis: Ulcerative colitis flare. Interventions: A subcutaneous golimumab with a loading dose of 200 mg at week 0, followed by 100 mg at week 2, then 50 mg every 4 weeks. Outcomes: The patient achieved clinical remission by week sixth and maintained the remission for the next 90 weeks. At the time of last evaluation, tests, including C-reactive protein and fecal calprotectin, were within normal limits, complete colonoscopy revealed erythema, edema, mucosal friability, loss of vascular patterns, and pseudo-polyps. The Pediatric Ulcerative Colitis Activity Index and Mayo scores were 5 and 2 points, respectively. No adverse events were documented. Conclusion: Golimumab has shown potential efficacy and safety in the treatment of ulcerative colitis in children which may indicate a significant future role for subcutaneous golimumab in pediatrics ulcerative colitis.

show abstract

Section: Discussionmentioning

confidence: 84%

“…[17,[46][47][48] We did not record any adverse events even though golimumab was maintained for >90 weeks during the COVID-19 pandemic. [49,50]…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis

Alhalabi¹,

Eddin²,

Cheha³

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…The experience of different countries during the pandemic period has shown that children, compared to adults, have a smoother disease course, lower respiratory tract lesion in the form of viral pneumonia is less typical, symptoms are usually mild, and mortality is extremely rare. Diarrhea in COVID-19 children is more common than in adults [10], [11] There is no evidence of prenatal infection vertical mother-to-child transmission. All cases are considered as acquired after birth.…”

Section: Clinical Manifestations and Characteristics Of Children Infe...mentioning

confidence: 99%

The Current Situation and Management of Omicron with Children in Russia: A Review

Гусев

Vladislav

Daun

et al. 2022

IJTDH

View full text Add to dashboard Cite

Omicron is a newly discovered new variant virus, which spreads rapidly around Russia and the world and has a great impact. It is designated as a variant of concern (VOC) by the World Health Organization. Its characteristic of epidemiology, distribution, pathogenic and clinical diagnosis, treatment, and prevention is still being observed and summarized, and Clinical manifestations of COVID-19 infection are nonspecific, especially in preterm infants. Since there are few reports on the diagnosis and treatment of children with this infection. This article studies the diagnosis, treatment, and prevention of omicron in Russian children, to improve the understanding and attention to the disease.

show abstract

Review of inflammatory bowel disease and COVID-19

Cited by 2 publications

References 34 publications

Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis

Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis

The Current Situation and Management of Omicron with Children in Russia: A Review

Contact Info

Product

Resources

About